eligibility_summary
Adults ≥18 with relapsed/refractory MCL after anti‑CD20+alkylator, ECOG 0–1, measurable FDG‑avid disease, tissue available, adequate organ function, controlled hepatitis, contraception. Exclude: pregnancy, prior BTKi major bleed/≥3 arrhythmia or progression on covalent BTKi, recent transplant/RT/CAR‑T/antibodies/immunosuppression/live vaccine, CNS involvement, active infection, significant CV/pulm or QTc>470, autoimmune (limited exceptions), warfarin, HIV, HLH, strong CYP3A need.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06252675 (Phase 2, single-arm) tests glofitamab plus pirtobrutinib with an obinutuzumab lead-in for relapsed/refractory mantle cell lymphoma. Drugs and mechanisms: • Glofitamab: a CD20×CD3 bispecific monoclonal antibody (T‑cell engager) that binds CD20 on B cells and CD3 on T cells to activate cytotoxic T cells and eliminate CD20+ lymphoma cells. • Obinutuzumab: a glycoengineered type II anti‑CD20 monoclonal antibody that depletes B cells (via ADCC and direct cell death) and is used to debulk and reduce cytokine‑release risk. • Pirtobrutinib (LOXO‑305): an oral, non‑covalent, reversible BTK inhibitor that blocks B‑cell receptor (BCR) signaling, active against wild‑type and C481‑mutant BTK. Targets/pathways: CD20 on malignant B cells, CD3 on T cells, BTK within the BCR pathway, driving proliferation/survival of MCL cells.